Harvey M Friedman

US Patent:

8057804, Nov 15, 2011

Filed:

Jul 24, 2008

Appl. No.:

12/179439

Inventors:

Harvey Friedman - Merion PA, US
Sita Awasthi - Bala Cynwyd PA, US
John Lubinski - Malvern PA, US

Assignee:

The Trustees of the University of Pennsylvania - Philadelphia PA

International Classification:

A61K 39/245

US Classification:

4242311

Abstract:

This invention provides vaccines comprising two or more recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of impeding immune evasion by HSV thereby vaccinating a subject against HSV and treating, suppressing, inhibiting, and/or reducing an incidence of an HSV infection or a symptom or manifestation thereof, comprising administration of a vaccine of the present invention.

US Patent:

20090098162, Apr 16, 2009

Filed:

Dec 27, 2007

Appl. No.:

12/005407

Inventors:

Harvey Friedman - Merion PA, US
Sita Awasthi - Bala Cynwid PA, US
John Lubinski - Malvern PA, US

International Classification:

A61K 39/245

US Classification:

4242311

Abstract:

This invention provides vaccines comprising two or more recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of vaccinating a subject against HSV and treating, impeding, inhibiting, reducing the incidence of, or suppressing an HSV infection or a symptom or manifestation thereof, comprising administration of a vaccine of the present invention.

US Patent:

20090246227, Oct 1, 2009

Filed:

Mar 31, 2009

Appl. No.:

12/415152

Inventors:

Harvey FRIEDMAN - Merion PA, US
Elizabeth E. ZUMBRUN - Middletown MD, US

International Classification:

A61K 39/245
A61P 31/22

US Classification:

4242311

Abstract:

This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated with same and inducing an anti-HSV immune response in a subject comprising the step of contacting the subject with a composition comprising a mutant HSV strain comprising an inactivating mutation in a Us8 gene, followed by a second contacting with the composition.

US Patent:

20110177125, Jul 21, 2011

Filed:

Sep 7, 2007

Appl. No.:

12/440223

Inventors:

Harvey Friedman - Merion PA, US
Elizabeth E. Zumbrun - Middletown MD, US
Fushan Wang - Broomall PA, US

International Classification:

A61K 39/245
C12N 7/04
A61P 31/22

US Classification:

4242311, 435236

Abstract:

This invention provides methods of vaccinating a subject against a Herpes Simplex Virus (HSV) infection and disorders and symptoms associated with same, and impeding, inhibiting, reducing the incidence of, and suppressing HSV infection, neuronal viral spread, formation of zosteriform lesions, herpetic ocular disease, herpes-mediated encephalitis, and genital ulcer disease in a subject, comprising the step of contacting the subject with a mutant strain of the HSV, containing an inactivating mutation in a gene encoding a gE, gl, Us9, or other proteins.

US Patent:

20110256176, Oct 20, 2011

Filed:

Nov 13, 2008

Appl. No.:

12/270772

Inventors:

Harvey FRIEDMAN - Merion PA, US
Sita AWASTHI - Bala Cynwyd PA, US
John LUBINSKI - Malvern PA, US

International Classification:

A61K 39/245
A61P 31/22
A61P 37/04

US Classification:

4242311

Abstract:

This invention provides vaccines comprising two or more recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of impeding immune evasion by HSV thereby vaccinating a subject against HSV and treating, suppressing, inhibiting, and/or reducing an incidence of an an HSV infection or a symptom or manifestation thereof, comprising administration of a vaccine of the present invention.

US Patent:

20120114695, May 10, 2012

Filed:

Mar 31, 2010

Appl. No.:

13/260835

Inventors:

Harvey M. Friedman - Merion PA, US
Elizabeth E. Brittle - Middletown MD, US
Fushan Wang - Broomall PA, US

International Classification:

A61K 39/245
A61P 31/22

US Classification:

4242311

Abstract:

This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated with same and inducing an anti-HSV immune response in a subject comprising the step of contacting the subject with a composition comprising a mutant HSV strain comprising an inactivating mutation in a Us8 gene, followed by a second contacting with the composition.

US Patent:

20130028925, Jan 31, 2013

Filed:

Jun 4, 2012

Appl. No.:

13/487966

Inventors:

Harvey FRIEDMAN - Merion PA, US
Sita Awasthi - Bala Cynwyd PA, US
John Lubinski - Malvern PA, US

International Classification:

A61K 39/245
A61P 31/22

US Classification:

4241861

Abstract:

This invention provides immunogenic compositions comprising two or three recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of impeding immune evasion by HSV, inducing an anti-HSV immune response, and treating, suppressing, inhibiting, and/or reducing an incidence of an HSV infection or a symptom or manifestation thereof, comprising administration of a vaccine of the present invention.

US Patent:

62876058, Sep 11, 2001

Filed:

Apr 16, 1999

Appl. No.:

9/293758

Inventors:

Daniel Malamud - Merion PA
Thandavarayan Nagashunmugam - Havertown PA
Harvey M. Friedman - Merion PA
William Abrams - Merion PA
Earl J. Bergey - South Dayton NY

Assignee:

The Trustees of the University of Pennsylvania - Philadelphia PA

International Classification:

A61K 3537

US Classification:

424550

Abstract:

The invention includes compositions comprising substantially purified salivary glycoproteins and carbohydrate ligands thereof which are useful in methods for the treatment and prevention of HIV-1 infection. The invention also includes methods for the treatment and prevention of HIV-1 infection comprising contacting a composition of the invention with a human patient. Additionally, the invention includes antibodies and kits useful in the treatment and prevention of HIV-1 infection.